Articles

Poll

Podcasts

Slideshows

Videos

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

An analysis of real-life data indicates the role of adalimumab in reducing the frequency and/or severity of ocular flares in pediatric patients with non-infectious non-anterior uveitis.

Real-World Evidence Supports Efficacy of Adalimumab for Pediatric Non-Anterior Uveitis

Data from the United Kingdom indicate Amgevita is safe and effective for non-infectious uveitis with non-inferiority to originator adalimumab, but a significant number of patients requested to switch back due to adverse events. 

Adalimumab Biosimilar for Uveitis Similarly Efficacious to Bio-Originator

A 0.18-mg implant may be an effective option in managing noninfectious uveitis affecting the posterior segment. 

Fluocinolone Acetonide Implant Could Be Effective for Noninfectious Uveitis

Eyes with concurrent uveitis in a Swedish cohort had worse BCVA prior to and following cataract surgery, although visual improvement was greater compared to control eyes.  

Cataract Surgery Linked to Greater Challenges in Eyes with Uveitis 

The retrospective study reported the presence of ADAs was associated with lower drug levels, and higher ADA levels were associated with increased risk of TNFi therapy failure. 

Antidrug Antibody Level Associated with TNFi Therapy Failure in Noninfectious Uveitis

The findings may support the use of macular imaging for monitoring at the time of glaucoma diagnosis and for monitoring the rate of GCC thinning.  

Rapid Initial GCC Thinning Associated with Faster Rates of Central Visual Field Loss 

A look into major takeaways on efficacy, safety and functional data from the DERBY and OAKS trials on pegcetacoplan. 

Charles Wykoff, MD, PhD: Shifting the Treatment Paradigm with Pegcetacoplan for GA 

Brolucizumab was deemed superior to aflibercept in treatment naive patients with neovascular age-related macular degeneration. 

Peter J Kertes, MD: Insights into the TALON Trial on Brolucizumab Versus Aflibercept

Study data suggest the observed to expected ratio of VAU for the United States cases reports was comparable for all 3 approved vaccines. 

Risk for Vaccine-Associated Uveitis Low After SARS-CoV-2 Vaccination 

The presence of SRF or PED was not significantly associated with worse visual acuity at any time point during the observation period.

Poorer Visual Outcomes in nAMD Treatment Linked to Intraretinal Fluid Presence

The HCPLive uveitis page is a comprehensive resource for clinical news and insights on chorioretinitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for eye inflammation, and more.